Technology
Health
Biotechnology

Alimera Sciences

$0.8793
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0026 (-0.30%) Today
+$0.0118 (1.36%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ALIM and other stocks, options, ETFs, and crypto commission-free!

About ALIM

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. Read More The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Employees
124
Headquarters
Alpharetta, Georgia
Founded
2003
Market Cap
61.75M
Price-Earnings Ratio
3.14
Dividend Yield
0.00
Average Volume
93.94K
High Today
$0.8794
Low Today
$0.8532
Open Price
$0.8717
Volume
91.52K
52 Week High
$1.21
52 Week Low
$0.7181

Collections

Technology
Health
Biotechnology
Research And Development
Biopharmaceutical
Pharmaceutical
US
North America

ALIM Earnings

-$0.11
-$0.08
-$0.05
-$0.02
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Jul 29, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.